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Lung cancer is the leading cause of cancer related deaths
in the United States with a 5 year survival of only 15%.
[1] The International Association for the Study of Lung
Cancer (IASLC) issued a 7th edition of the TNM staging
system for lung cancer in 2007. [2] It includes several
revisions which better align TNM staging with prognosis
and in some cases with treatment.
There have been revisions in the TNM descriptors. In
the T or tumor category, the T1 and T2 categories
include now subcategorization of size with new T1a, T1b,
T2a and T2b subdescriptors. One of the important
changes is that tumors larger than 7 cm are now consid-
ered Stage T3 tumors. Stage IV tumors include separate
tumor nodules in the same lung but not in the same lobe
as the primary lesion which were previously considered
metastatic (M1). Stage T4 disease is now downgraded to
Stage III when satellite nodules are present in the same
lobe as the primary lesion. The presence of malignant
pleural effusion, pleural dissemination or pericardial dis-
ease is now considered metastatic disease, specifically
stage M1a for local intrathoracic disease rather than
Stage IV disease [3-5].
Although the IASLC has proposed a new lymph node
map there are no changes to the end descriptors in the
7th edition of the TNM staging system [3-5].
Nearly one half of newly diagnosed lung cancers
already demonstrate metastases within the lung, brain,
liver, and bony structures. Any metastatic disease is
automatically designated Stage IV disease and with few
exceptions is considered surgically unresectable. The M
category is now subcategorized into intra-thoracic
metastasis M1a and extra-thoracic metastatic M1b with
the former having a better prognosis [4].
Contrast enhanced CT remains the mainstay for staging
of lung cancer. However, PET has particular value in
nodal staging of lung cancer and also in determining the
presence of distant metastatic disease. In a study by
Gould et al, the sensitivity of PET CT for metastasis was
85% and the specificity was 95% as compared with a CT
sensitivity of 61% and specificity of 79% [6]. PET CT does
have a high false positive rate so it cannot replace invasive
sampling, but it may be used to direct invasive staging.
PET scanning is particularly useful in M staging of non-
small cell lung cancer. PET can replace the use of bone
scintigraphy and it is now widely used for determination
of distant metastasis throughout the body. However, it is
limited in the assessment of brain metastases. In the PLUS
Trial, 188 patients with potentially resectable non-small
cell lung cancer were randomized to either conventional
work up or PET CT. Addition of the PET CT to the
conventional work up prevented future surgery in 1 out of
5 patients [7].
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